미국 · 보도자료 · NovaBridge Biosciences · 2026-10-08 20:05
기바스토밉 확장 임상 1b상 안전성·유효성 데이터 ESMO 2026서 발표
ROCKVILLE, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ: NBP) today announced that updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in participants with previously untreated, HER2-negative, CLDN18.2-positive, and PD-L1-positive locally advanced
NovaBridge Biosciences 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
